Fig. 6: Small-molecule inhibitor of IGF2BP2 as a strategy against T-ALL.
From: Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia
A Small-molecule inhibitor JX5. Chemical structure JX5 (left side). 3D (left) and surface (right) view models show the binding pocket and binding of IGF2BP2 and JX5. Molecular docking of JX5 with IGF2BP2 (PDB: 6ROL) were performed (right side). B Cell growth inhibition of Jurkat cells (oeIGF2BP2 or NC, shIGF2BP2 or shNC) were assessed by CCK8 assays after 48 h treatment with serial dilutions of JX5. C Proliferation of Jurkat cells (oeIGF2BP2 or NC, shIGF2BP2 or shNC) treated with 25uM JX5 were assessed by CCK8 assays, and proliferation rates at 0, 12, 24, 48, 72 and 96 h were normalized to the absorbance at 0 h. Data are mean ± SD values. *P < 0.05; **P < 0.01; ***P < 0.001.
